DOP2017000084A - Composición farmacéutica sólida que comprende amlodipino y losartán - Google Patents

Composición farmacéutica sólida que comprende amlodipino y losartán

Info

Publication number
DOP2017000084A
DOP2017000084A DO2017000084A DO2017000084A DOP2017000084A DO P2017000084 A DOP2017000084 A DO P2017000084A DO 2017000084 A DO2017000084 A DO 2017000084A DO 2017000084 A DO2017000084 A DO 2017000084A DO P2017000084 A DOP2017000084 A DO P2017000084A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical composition
losartán
amlodipino
composition including
solid pharmaceutical
Prior art date
Application number
DO2017000084A
Other languages
English (en)
Inventor
Hyun Park Jae
Soo Woo Jong
Taek Im Ho
Ii Kim Yong
Su Yoon Young
Roh Leedong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of DOP2017000084A publication Critical patent/DOP2017000084A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención proporciona una composición farmacéutica para la prevención o el tratamiento de trastornos cardiovasculares que contienen losartán o una sal farmacéuticamente aceptable del mismo; amlodipino o una sal farmacéuticamente aceptable del mismo; un desintegrante; y un agente de revestimiento. La composición de la presente invención, la cual tiene la mejor combinación y relación óptima de un desintegrante a un agente de revestimiento, muestra resistencia suficiente y altas tasas de disolución bajo varios ambientes de pH, y de esta manera, es útil para la preparación de una formulación sólida excelente que muestra eficiencia de suministro de fármaco y estabilidad de almacenamiento mejoradas. FIG. 1
DO2017000084A 2014-09-30 2017-03-24 Composición farmacéutica sólida que comprende amlodipino y losartán DOP2017000084A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140131834 2014-09-30

Publications (1)

Publication Number Publication Date
DOP2017000084A true DOP2017000084A (es) 2017-07-31

Family

ID=55630854

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000084A DOP2017000084A (es) 2014-09-30 2017-03-24 Composición farmacéutica sólida que comprende amlodipino y losartán

Country Status (20)

Country Link
US (1) US10034862B2 (es)
JP (1) JP2017530137A (es)
KR (1) KR102369607B1 (es)
CN (2) CN107018650B (es)
AR (1) AR101860A1 (es)
CO (1) CO2017003913A2 (es)
CR (1) CR20170125A (es)
DO (1) DOP2017000084A (es)
EC (1) ECSP17022124A (es)
JO (1) JO3435B1 (es)
MX (1) MX377103B (es)
MY (1) MY188302A (es)
PH (1) PH12017500536A1 (es)
RU (1) RU2698703C2 (es)
SG (1) SG11201702364VA (es)
SV (1) SV2017005417A (es)
TW (1) TWI681773B (es)
UY (1) UY36331A (es)
WO (1) WO2016052866A1 (es)
ZA (1) ZA201703015B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
WO2018093096A2 (en) * 2016-11-15 2018-05-24 Hanmi Pharm. Co., Ltd. Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
KR20210152943A (ko) * 2020-06-09 2021-12-16 한미약품 주식회사 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
AU685898B2 (en) 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
US20110206761A1 (en) * 2008-09-04 2011-08-25 Nishant Babanrao Naware Stable dosage forms of antihypertensive agents
MA33056B1 (fr) * 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
KR101888692B1 (ko) * 2011-03-25 2018-09-20 한미사이언스 주식회사 로자탄, 암로디핀 및 히드로클로로티아지드를 함유하는 고정 조합 투여 제형 조성물
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물

Also Published As

Publication number Publication date
ZA201703015B (en) 2019-07-31
SG11201702364VA (en) 2017-05-30
AR101860A1 (es) 2017-01-18
ECSP17022124A (es) 2018-05-31
TW201617075A (zh) 2016-05-16
MX2017004032A (es) 2017-07-07
WO2016052866A1 (en) 2016-04-07
SV2017005417A (es) 2017-10-13
MY188302A (en) 2021-11-26
US20170326110A1 (en) 2017-11-16
JO3435B1 (ar) 2019-10-20
KR102369607B1 (ko) 2022-03-03
RU2698703C2 (ru) 2019-08-29
CN112716951A (zh) 2021-04-30
KR20160038734A (ko) 2016-04-07
CN107018650A (zh) 2017-08-04
TWI681773B (zh) 2020-01-11
CR20170125A (es) 2017-07-06
CO2017003913A2 (es) 2017-04-28
PH12017500536A1 (en) 2017-08-07
RU2017114993A (ru) 2018-11-05
US10034862B2 (en) 2018-07-31
RU2017114993A3 (es) 2019-04-05
JP2017530137A (ja) 2017-10-12
CN107018650B (zh) 2021-02-02
MX377103B (es) 2025-03-07
UY36331A (es) 2016-04-29

Similar Documents

Publication Publication Date Title
IL262581B1 (en) Production methods, preparations and medical applications of drugs containing cannabis for oral administration
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
SA516380290B1 (ar) نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة
EP3808367A3 (en) Targeting aneurysm disease by modulating phagocytosis pathways
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2017016524A (es) Sistemas de administracion para liberacion controlada de farmacos.
MX2018001584A (es) Composiciones de solución sólida para aines.
EP3318282A4 (en) AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
DOP2017000084A (es) Composición farmacéutica sólida que comprende amlodipino y losartán
MX2017012459A (es) Formulacion de complejo farmaceutico que comprende amlodipina, losartan y clortalidona.
CL2017000026A1 (es) Formas de dosificación farmacéutica
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
WO2015104298A3 (de) Polyphenol-konjugate
EA201791648A1 (ru) Комбинация гиалуроновой кислоты и макроголя и фармацевтические композиции, содержащие ее
DOP2019000190A (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla.
TN2016000479A1 (en) Nitisinone dosing regimens for the treatment of alkaptonuria.
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EA201991190A1 (ru) Фармацевтический комплексный препарат, содержащий амлодипин, лозартан и розувастатин
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид
TH1601001372A (th) สารประกอบอะซา-ไพริโดน และการใช้งานของพวกมัน
TH165164A (th) สูตรผสมเชิงประกอบทางเภสัชกรรมของแคปซูลที่ประกอบรวมด้วยทาดาลาฟิล และแทมซูโลซิน